Is MNICF Stock Undervalued?

A comprehensive valuation analysis of Mani, Inc. (MNICF) examining current multiples, intrinsic value, and comparing to analyst expectations.

Updated January 21, 2026•8 min read•View Full Analysis

Valuation Verdict

↑

Potentially Undervalued

445066159628.5% upside potential

Based on our analysis, Mani, Inc. appears to be potentially undervalued at the current price of $12.82. Our fair value estimate of $57057481677.20 suggests upside potential of approximately 445066159628.5%.

Current Valuation Metrics

Valuation ratios help us understand how the market is pricing MNICF relative to its fundamentals. Let's examine the key multiples investors are paying today.

P/E Ratio

30.52

High

P/B Ratio

3.70

High

P/S Ratio

0.04

Low

EV/EBITDA

14.47

Moderate

Understanding the Metrics

P/E Ratio: At 30.52x earnings, MNICF is trading above the typical market average of 15-20x.
P/B Ratio: A P/B of 3.70 means investors pay $3.70 for every $1 of book value.
P/S Ratio: The price-to-sales ratio of 0.04 indicates how much investors value each dollar of revenue.
EV/EBITDA: This ratio of 14.47 helps compare MNICF to peers while accounting for debt.

Fair Value Estimate

Using a discounted cash flow (DCF) model, we estimate the intrinsic value of Mani, Inc. stock. This fundamental analysis looks at the company's ability to generate future cash flows and discounts them back to today's value.

Current Price

$12.82

Fair Value Estimate

$57057481677.20

Implied Return+445066159628.5%

Our DCF model suggests MNICF may be undervalued by approximately 445066159628.5%. This implies the market may be pricing in more pessimistic growth expectations than our base case scenario.

Investment Conclusion

Bottom Line

Based on our comprehensive valuation analysis, Mani, Inc. (MNICF) appears to be undervalued at $12.82. With a fair value estimate of $57057481677.20, the stock offers potential upside for long-term investors willing to wait for the market to recognize its intrinsic value.

Disclaimer: This analysis is for informational purposes only and should not be considered investment advice. Always conduct your own research and consult with a financial advisor before making investment decisions. Past performance does not guarantee future results.